Male hormones and men's quality of life

Current Opinion in Urology

Volumn 26, Issue 2, 2016, Pages 152-157

  Khera, Mohit ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

hormone; quality of life; testosterone

Indexed keywords

ANDROSTANOLONE; CONTRACEPTIVE AGENT; ESTRADIOL; TESTOSTERONE; ANDROGEN;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DEPRESSION; DIABETES MELLITUS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MALE FERTILITY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL FUNCTION; SYSTEMATIC REVIEW (TOPIC); BLOOD; CHEMICALLY INDUCED; DEFICIENCY; FERTILITY; METABOLISM; REPRODUCTION;

ANDROGENS; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASES; DEPRESSION; ESTRADIOL; FERTILITY; HUMANS; INSULIN RESISTANCE; MALE; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; REPRODUCTION; TESTOSTERONE;

EID: 84954349505     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000256     Document Type: Review

References (62)

1. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57:127-132.
2. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787-2791.
3. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407-413.
4. Murray MP, Gardner GM, Mollinger LA, Sepic SB. Strength of isometric and isokinetic contractions: Knee muscles of men aged 20 to 86. Phys Ther 1980; 60:412-419.
5. Moffat SD, Zonderman AB, Metter EJ, et al. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002; 87:5001-5007.
6. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358-4365.
7. Davidson JM, Chen JJ, Crapo L, et al. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983; 57:71-77.
8. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol Spring 2005; 7:87-94.
9. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2839-2853.
10. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510.
11. Miller NL, Fulmer BR. Injection, ligation and transplantation: The search for the glandular fountain of youth. J Urol 2007; 177:2000-2005.
12. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study. J Clin Endocrinol Metab 2008; 93:2737- 2745.
13. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006; 60:762-769.
14. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89:5920-5926.
15. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92:4241-4247.
16. Khera M, Bhattacharya RK, Blick G, et al. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012; 15:14-21.
17. Guay AT, Traish A. Testosterone deficiency and risk factors in the metabolic syndrome: Implications for erectile dysfunction. Urol Clin North Am 2011; 38:175-183.
18. Lugg J, Ng C, Rajfer J, Gonzalez-Cadavid N. Cavernosal nerve stimulation in the rat reverses castration-induced decrease in penile NOS activity. Am J Physiol 1996; 271 (2 Pt 1):E354-361.
19. Garban H, Marquez D, Cai L, et al. Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens. Biol Reprod 1995; 53:1365-1372.
20. Baba K, Yajima M, Carrier S, et al. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int 2000; 85:953-958.
21. Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol 2005; 63:381- 394.
22. Bolona ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: A systematic review and meta-analysis of randomized placebocontrolled trials. Mayo Clin Proc 2007; 82:20-28.
23. Mikhail N. Does testosterone have a role in erectile function?. Am J Med 2006; 119:373-382.
24. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011; 8:284-293.
25. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172:658-663.
26. Pope HG Jr, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160:105-111.
27. Singh J, O'Neill C, Handelsman DJ. Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology 1995; 136:5311- 5321.
28. Sharpe RM, Kerr JB, McKinnell C, Millar M. Temporal relationship between androgen-dependent changes in the volume of seminiferous tubule fluid, lumen size and seminiferous tubule protein secretion in rats. J Reprod Fertil 1994; 101:193-198.
29. Cooper TG. Epididymis and sperm function. Andrologia 1996; 28 (Suppl 1):57-59.
30. Sun YT, Irby DC, Robertson DM, de Kretser DM. The effects of exogenously administered testosterone on spermatogenesis in intact and hypophysectomized rats. Endocrinology 1989; 125:1000-1010.
31. McLachlan RI, O'Donnell L, Meachem SJ, et al. Hormonal regulation of spermatogenesis in primates and man: Insights for development of the male hormonal contraceptive. J Androl 2002; 23:149-162.
32. Weinbauer GF, Nieschlag E. Gonadotrophin-releasing hormone analogueinduced manipulation of testicular function in the monkey. Hum Reprod 1993; 8 (Suppl 2):45-50.
33. WHO Task Force. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 1990; 336:955-959.
34. Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: From physiology to clinical implications. Eur Urol 2014; 65:115-123.
35. Song W, Khera M. Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro. Asian J Androl 2014; 16:864-868.
36. Calof OM, Singh AB, Lee ML, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60:1451-1457.
37. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: A systematic review. Int J Impot Res 2009; 21:9-23.
38. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011; 52:657-663.
39. Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: An experimental study in rabbit. J Endocrinol 2012; 212:71-84.
40. Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male 2008; 11:51-55.
41. Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study. Aging Male 2011; 14:53-58.
42. Kalinchenko S, Vishnevskiy EL, Koval AN, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with lateonset hypogonadism: A pilot study. Aging Male 2008; 11:57-61.
43. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clinical endocrinology 2005; 63:280-293.
44. Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91:2011-2016.
45. Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with lateonset hypogonadism and metabolic syndrome: Results from a 36 months controlled study. Aging Male 2012; 15:96-102.
46. Bhasin S, Taylor WE, Singh R, et al. The mechanisms of androgen effects on body composition: Mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci 2003; 58:M1103-1110.
47. Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab 2006; 91:3024- 3033.
48. Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2:146-159.
49. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. Engl J Med 2010; 363:109-122.
50. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, doubleblind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650.
51. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl Jan-Feb 2009; 30:23-32.
52. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30:726-733.
53. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34:828-837.
54. Morgentaler A. Testosterone, cardiovascular risk, and hormonophobia. J Sex Med 2014; 11:1362-1366.
55. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: A systematic review and meta-analysis. Expert Opin Drug Saf 2014; 13:1327-1351.
56. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829-1836.
57. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of nonfatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805.
58. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166:1660-1665.
59. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93:68-75.
60. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369:2457.
61. Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61:579-584.
62. Kunelius P, Lukkarinen O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study. J Clin Endocrinol Metab 2002; 87:1467-1472.